US Patent

US9586955 — Compounds for treating spinal muscular atrophy

Composition of Matter · Assigned to F Hoffmann La Roche AG · Expires 2033-02-08 · 7y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds of Formula (I) and their forms, compositions, and uses for treating spinal muscular atrophy.

USPTO Abstract

Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.

Drugs covered by this patent

Patent Metadata

Patent number
US9586955
Jurisdiction
US
Classification
Composition of Matter
Expires
2033-02-08
Drug substance claim
Yes
Drug product claim
Yes
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.